MHRA approves Seagen’s oral HER2 drug TukysaThe UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after Share XMHRA approves Seagen’s oral HER2 drug Tukysahttps://pharmaphorum.com/news/mhra-approves-seagens-oral-her2-drug-tukysa/
2021 – UK market access prospectsWith a new year comes the opportunity to think ahead for the market access landscape for the coming Share X2021 – UK market access prospectshttps://pharmaphorum.com/views-analysis-market-access/2021-uk-market-access-prospects/
Moderna’s COVID-19 vaccine is third approved in UKThe UK has approved the Moderna coronavirus vaccine, hard on the heels of its go-ahead in Europe, although Share XModerna’s COVID-19 vaccine is third approved in UKhttps://pharmaphorum.com/news/modernas-covid-19-vaccine-is-third-approved-in-uk/
AZ COVID-19 vaccine cleared in UK, dosing to start next weekThe UK has approved AstraZeneca and Oxford University’s COVID-19 vaccine AZD1222 in another significant step forward in the Share XAZ COVID-19 vaccine cleared in UK, dosing to start next weekhttps://pharmaphorum.com/news/az-covid-19-vaccine-cleared-in-uk-dosing-to-start-next-week/
FDA aims for fast approval of Moderna’s COVID-19 shot after panel voteThe FDA is looking to quickly approve Moderna’s COVID-19 vaccine after it was unanimously backed by a panel Share XFDA aims for fast approval of Moderna’s COVID-19 shot after panel votehttps://pharmaphorum.com/news/fda-aims-for-fast-approval-of-modernas-covid-19-shot-after-panel-vote/
Social media erupts as anti-vaxxers respond to COVID-19 vaccine approvalIn the midst of the jubilation about the UK’s emergency approval of Pfizer/BioNTech’s COVID-19 shot in the UK Share XSocial media erupts as anti-vaxxers respond to COVID-19 vaccine approvalhttps://pharmaphorum.com/news/social-media-erupts-as-anti-vaxxers-respond-to-covid-19-vaccine-approval/
MHRA looks to AI to hunt for COVID-19 vaccine side effectsThe UK drugs regulator has awarded a £1.5 million tender to a software company for an artificial intelligence Share XMHRA looks to AI to hunt for COVID-19 vaccine side effectshttps://pharmaphorum.com/news/mhra-looks-to-ai-to-hunt-for-covid-19-vaccine-side-effects/
MHRA publishes guidance on medicine regulation after BrexitThe UK’s medicines regulator has published long-awaited guidance on regulation of medicines and medical devices as the UK Share XMHRA publishes guidance on medicine regulation after Brexithttps://pharmaphorum.com/news/mhra-publishes-guidance-on-medicine-regulation-after-brexit/
UK patients get early access to Alnylam’s ultra-rare disease drug lumasiranThe UK’s regulator has granted early access to Alnylam’s ultra-rare disease drug lumasiran, allowing patients with primary hyperoxaluria Share XUK patients get early access to Alnylam’s ultra-rare disease drug lumasiranhttps://pharmaphorum.com/news/uk-patients-get-early-access-to-alnylams-ultra-rare-disease-drug-lumasiran/
